State MI
Clinical Trials in Michigan
Recruiting clinical trials with at least one study location in Michigan. Data updated daily from ClinicalTrials.gov.
Top Conditions in Michigan
Advanced Solid Tumor (6)Advanced Solid Tumors (5)Glioma (4)Multiple Myeloma (4)Metastatic Breast Cancer (4)Parkinson Disease (4)Stage IVB Prostate Cancer AJCC v8 (4)Breast Cancer (4)Chronic Lymphocytic Leukemia (4)Prostate Cancer (4)Non-Small Cell Lung Cancer (3)Head and Neck Squamous Cell Carcinoma (3)
Frequently Asked Questions — Clinical Trials in Michigan
How many clinical trials are currently recruiting in Michigan?
ClinicalMetric currently tracks 345 actively recruiting clinical trials with at least one location in Michigan. The total number of registered studies—including active but not currently enrolling trials—is 345. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Michigan?
Michigan hosts clinical trials across a broad range of medical conditions, including Advanced Solid Tumor, Advanced Solid Tumors, Glioma, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Michigan serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Michigan?
To join a clinical trial in Michigan, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Michigan maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Michigan
NCT01356290 Phase 2
Recruiting
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ...
Condition
Medulloblastoma Recurrent
Enrollment
232 pts
Location
United States, Austria, Czechia
Sponsor
Medical University of Vienna
NCT04181060 Phase 3
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With E...
Condition
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Enrollment
300 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT06100289 Phase 3
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Croh...
Condition
Ulcerative Colitis
Enrollment
70 pts
Location
United States, Belgium, Bulgaria
Sponsor
Takeda
NCT05986890 N/A
Recruiting
Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Out...
Condition
Malignant Gastric Outlet Obstruction
Enrollment
16 pts
Location
United States
Sponsor
Corewell Health West
NCT06770582 Phase 2
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Ther...
Condition
Non-Muscle Invasive Bladder Urothelial Carcinoma
Enrollment
160 pts
Location
United States, Canada
Sponsor
National Cancer Institute (NCI
NCT04752774 Phase 1, Phase 2
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With...
Condition
Spasticity
Enrollment
240 pts
Location
United States, Austria, Bulgaria
Sponsor
Ipsen
NCT05573126 Phase 1, Phase 2
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients...
Condition
Hormone Receptor-positive Breast Cancer
Enrollment
95 pts
Location
United States, Spain, United Kingdom
Sponsor
Ellipses Pharma
NCT05828069 Phase 2
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapse...
Condition
Recurrent Langerhans Cell Histiocytosis
Enrollment
48 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT06967805 Phase 2
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis...
Condition
Idiopathic Pulmonary Fibrosis
Enrollment
164 pts
Location
United States, Argentina, Australia
Sponsor
Mediar Therapeutics
NCT05533697 Phase 1, Phase 2
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint ...
Condition
Advanced Solid Tumors
Enrollment
361 pts
Location
United States, Australia, Spain
Sponsor
ModernaTX, Inc.
NCT06143956 Phase 2
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices ...
Condition
Obesity
Enrollment
1,217 pts
Location
United States, Argentina
Sponsor
Eli Lilly and Company
NCT06963827 Phase 3
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Condition
Kidney Disease
Enrollment
347 pts
Location
United States, Argentina, Australia
Sponsor
Takeda
NCT06567886 N/A
Recruiting
Fibromyalgia Sleep A to ZZZ Study
Condition
Fibromyalgia
Enrollment
390 pts
Location
United States
Sponsor
University of Michigan
NCT06933160 N/A
Recruiting
Promotion of Exercise Through Physical Therapy for Multiple Sclerosis: A Pilot S...
Condition
Multiple Sclerosis
Enrollment
40 pts
Location
United States
Sponsor
University of Michigan
NCT06165341 Phase 3
Recruiting
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alp...
Condition
Alpha1-Antitrypsin Deficiency
Enrollment
50 pts
Location
United States, Austria, Belgium
Sponsor
Takeda
NCT05611242 Phase 3
Recruiting
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlu...
Condition
Acute Ischemic Stroke
Enrollment
404 pts
Location
United States
Sponsor
Mercy Health Ohio
NCT06944522 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Ha...
Condition
Parkinsons Disease (PD)
Enrollment
102 pts
Location
United States, Australia, Canada
Sponsor
BlueRock Therapeutics
NCT07543861 Phase 1
Recruiting
A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease
Condition
Parkinson Disease
Enrollment
5 pts
Location
United States
Sponsor
University of Michigan
NCT07136779 Phase 1, Phase 2
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Maligna...
Condition
Participants With Advanced Solid Tumor Malignancies
Enrollment
310 pts
Location
United States
Sponsor
VelaVigo Bio Inc
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study...
Condition
H3 K27M
Enrollment
510 pts
Location
United States, Argentina, Australia
Sponsor
Jazz Pharmaceuticals
NCT04879329 Phase 2
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th...
Condition
Urothelial Carcinoma
Enrollment
372 pts
Location
United States, Argentina, Australia
Sponsor
Seagen, a wholly owned subsidi
NCT06976203 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Imp...
Condition
Alzheimer's Disease
Enrollment
586 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT02852031 N/A
Recruiting
National Collaborative to Improve Care of Children With Complex Congenital Heart...
Condition
Hypoplastic Left Heart Syndrome (HLHS)
Enrollment
1,000 pts
Location
United States, Canada, United Kingdom
Sponsor
Children's Hospital Medical Ce
NCT07037888 Phase 4
Recruiting
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Pr...
Condition
Femoracetabular Impingement
Enrollment
100 pts
Location
United States
Sponsor
Henry Ford Health System
NCT06457503 Phase 4
Recruiting
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Particip...
Condition
Nasopharyngeal Cancer Recurrent
Enrollment
100 pts
Location
United States, Canada
Sponsor
Coherus Oncology, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology